Artificial Intelligence In Genomics Market by Offering (Software & Services), Technology (Machine Learning), Functionality (Gene Sequencing, Gene Editing), Application (Diagnostics, Drug discovery), End User (Pharma, Hospitals) - Global Forecasts to 2028
The artificial intelligence (AI) in genomics market is anticipated to grow from an estimated USD 0.5 billion in 2023 to USD 2.0 billion in 2028, at a CAGR of 32.3% during the forecast period. The market has a promising growth potential due to the need to accelerate processes and timeline and reduce drug development and discovery, and improving computing power and declining hardware cost among other factors. However, the lack of curated genomic data and data privacy concerns are expected to limit the growth of this market to a certain extent.
“Deep learning: The fastest-growing segment of the artificial intelligence (AI) in genomics market for machine learning, by type“
The deep learning segment is expected to witness the fastest growth in the infection surveillance services market during the forecast. Deep learning methods have dominated computational modeling strategies in genomics, where they are used to address a variety of questions ranging from the understanding of protein binding from DNA sequences, epigenetic modifications, predicting gene expression from epigenetic marks, or predicting the methylation state of single cells. The growing demand for accelerated genome sequencing analysis workflows and the need to improve the function of gene editing tools is expected to propel market growth.
“The genome sequencing segment is anticipated to be the largest artificial intelligence (AI) in genomics market, by functionality, during the forecast period”
Based on functionality, the market is segmented into genome sequencing, gene editing, clinical workflows, and predictive genetic testing & preventive medicine. The genome sequencing segment accounted for the largest share of the artificial intelligence (AI) in genomics market. The large share of this segment can be attributed to the use of AI solutions to identify chromosomal disorders, dysmorphic syndromes, teratogenic disorders, and single-gene disorders.
“Europe accounted for the second-largest share in the artificial intelligence (AI) in genomics market during the forecast period”
Europe accounted for the second-largest share of the artificial intelligence (AI) in genomics market during the forecast period. The major drivers of market growth are the increasing adoption of AI-based tools in genomic research and drug discovery, favorable government initiatives, growing EMR adoption, increasing patient data volume, increasing venture capital funding, rising healthcare expenditure, and growing geriatric population. Moreover, the potential for AI in advancing R&D activities has also attracted attention to this sector.
Break of primary participants was as mentioned below:
The key players operating in the artificial intelligence (AI) in genomics market include NVIDIA Corporation (US), Microsoft Corporation (US), Google, Inc. (US), Intel Corporation (US), BenevolentAI (UK), SOPHiA GENETICS (Switzerland), Illumina, Inc. (US), Predictive Oncology, Inc. (US), Invitae Corporation (US), Deep Genomics, Inc. (Canada), Fabric Genomics, Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch, Inc. (US), Dante labs (US), Data4Cure (US), PrecisionLife Ltd (UK), Genoox (US), Lifebit (UK), FDNA, Inc. (US), DNAnexus (US), Engine Biosciences (US), Tempus Labs, Inc. (US), Congenica Ltd (England), Emedgene, Inc. (US), and Seragon Pharmaceuticals, Inc. (US).
Research Coverage:
The report analyzes the artificial intelligence (AI) in genomics market and aims at estimating the market size and future growth potential of this market based on various segments such as offering, technology, functionality, application, end user, and region. The report also includes a product portfolio matrix of various artificial intelligence (AI) in genomics products & services available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
“Deep learning: The fastest-growing segment of the artificial intelligence (AI) in genomics market for machine learning, by type“
The deep learning segment is expected to witness the fastest growth in the infection surveillance services market during the forecast. Deep learning methods have dominated computational modeling strategies in genomics, where they are used to address a variety of questions ranging from the understanding of protein binding from DNA sequences, epigenetic modifications, predicting gene expression from epigenetic marks, or predicting the methylation state of single cells. The growing demand for accelerated genome sequencing analysis workflows and the need to improve the function of gene editing tools is expected to propel market growth.
“The genome sequencing segment is anticipated to be the largest artificial intelligence (AI) in genomics market, by functionality, during the forecast period”
Based on functionality, the market is segmented into genome sequencing, gene editing, clinical workflows, and predictive genetic testing & preventive medicine. The genome sequencing segment accounted for the largest share of the artificial intelligence (AI) in genomics market. The large share of this segment can be attributed to the use of AI solutions to identify chromosomal disorders, dysmorphic syndromes, teratogenic disorders, and single-gene disorders.
“Europe accounted for the second-largest share in the artificial intelligence (AI) in genomics market during the forecast period”
Europe accounted for the second-largest share of the artificial intelligence (AI) in genomics market during the forecast period. The major drivers of market growth are the increasing adoption of AI-based tools in genomic research and drug discovery, favorable government initiatives, growing EMR adoption, increasing patient data volume, increasing venture capital funding, rising healthcare expenditure, and growing geriatric population. Moreover, the potential for AI in advancing R&D activities has also attracted attention to this sector.
Break of primary participants was as mentioned below:
- By Company Type – Tier 1–40%, Tier 2–35%, and Tier 3–25%
- By Designation – C-level–35%, Director-level–25%, Others–40%
- By Region – North America–45%, Europe–30%, Asia Pacific–20%, and Rest of the World–5%
The key players operating in the artificial intelligence (AI) in genomics market include NVIDIA Corporation (US), Microsoft Corporation (US), Google, Inc. (US), Intel Corporation (US), BenevolentAI (UK), SOPHiA GENETICS (Switzerland), Illumina, Inc. (US), Predictive Oncology, Inc. (US), Invitae Corporation (US), Deep Genomics, Inc. (Canada), Fabric Genomics, Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch, Inc. (US), Dante labs (US), Data4Cure (US), PrecisionLife Ltd (UK), Genoox (US), Lifebit (UK), FDNA, Inc. (US), DNAnexus (US), Engine Biosciences (US), Tempus Labs, Inc. (US), Congenica Ltd (England), Emedgene, Inc. (US), and Seragon Pharmaceuticals, Inc. (US).
Research Coverage:
The report analyzes the artificial intelligence (AI) in genomics market and aims at estimating the market size and future growth potential of this market based on various segments such as offering, technology, functionality, application, end user, and region. The report also includes a product portfolio matrix of various artificial intelligence (AI) in genomics products & services available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
- Market Penetration: Comprehensive information on product portfolios offered by the top players in the global artificial intelligence (AI) in genomics market. The report analyzes this market by product & service and end user.
- Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global artificial intelligence (AI) in genomics market
- Market Development: Comprehensive information on the lucrative emerging markets by products & services and end user
- Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global artificial intelligence (AI) in genomics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global artificial intelligence (AI) in genomics market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.5 YEARS CONSIDERED
1.6 CURRENCY CONSIDERED
TABLE 1 CURRENCY CONVERSION RATES
1.7 LIMITATIONS
1.8 STAKEHOLDERS
1.9 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
FIGURE 3 RESEARCH APPROACH
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 KEY METRICS FOR ASSESSING SUPPLY OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
FIGURE 7 REVENUES GENERATED BY COMPANIES FROM SALE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS SOLUTIONS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 9 BOTTOM-UP APPROACH
FIGURE 10 ESTIMATION OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SIZE BASED ON ADOPTION
FIGURE 11 TOP-DOWN APPROACH
TABLE 2 FACTOR ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
FIGURE 13 ASSUMPTIONS FOR RESEARCH STUDY
2.5 IMPACT OF RECESSION
2.6 RISK ASSESSMENT
TABLE 3 LIMITATIONS AND ASSOCIATED RISKS
2.7 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 14 SOFTWARE SEGMENT TO LEAD ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
FIGURE 15 MACHINE LEARNING CONTINUES TO ACQUIRE LARGEST SIZE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
FIGURE 16 DEEP LEARNING TO BE FASTEST-GROWING SEGMENT OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING
FIGURE 17 GENOME SEQUENCING TO REGISTER HIGHEST CAGR IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
FIGURE 18 DIAGNOSTICS TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SECURE LEADING POSITION IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
FIGURE 20 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
FIGURE 21 INCREASING ADOPTION OF ARTIFICIAL INTELLIGENCE (AI) SOLUTIONS FOR DRUG DISCOVERY & DEVELOPMENT AND PRECISION MEDICINE TO DRIVE MARKET
4.2 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
FIGURE 22 NORTH AMERICA TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET DURING FORECAST PERIOD
4.3 NORTH AMERICAN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER AND COUNTRY, 2022
FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US DOMINATED MARKET IN NORTH AMERICA IN 2022
4.4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
FIGURE 24 SOFTWARE SEGMENT TO HOLD MAJORITY MARKET SHARE IN 2028
4.5 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
FIGURE 25 MACHINE LEARNING TO SURPASS OTHER TECHNOLOGIES IN 2028
4.6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028
4.7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
FIGURE 27 GENOME SEQUENCING TO BE FASTEST-GROWING SEGMENT DURING FORECAST PERIOD
4.8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
FIGURE 28 DIAGNOSTICS TO DOMINATE MARKET IN 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Need to accelerate processes and timeline and reduce drug development & discovery costs
5.2.1.2 Increased partnerships and collaborations among players and growing investments in AI in genomics
5.2.1.3 Rising adoption of AI in precision medicine
5.2.1.4 Explosion in bioinformatics data and genomic datasets
FIGURE 29 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023
5.2.1.5 Improving computing power and declining hardware cost
5.2.2 RESTRAINTS
5.2.2.1 Lack of skilled AI workforce and ambiguous regulatory guidelines for medical software
5.2.3 OPPORTUNITIES
5.2.3.1 Focus on developing human-aware AI systems
5.2.4 CHALLENGES
5.2.4.1 Lack of curated genomic data
5.2.4.2 Data privacy concerns
FIGURE 30 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2019–2021
5.3 ECOSYSTEM ANALYSIS
FIGURE 31 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: ECOSYSTEM ANALYSIS
6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
6.1 INTRODUCTION
FIGURE 32 SOFTWARE SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022
TABLE 4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
6.2 SOFTWARE
6.2.1 INTELLIGENT SOFTWARE TO REDUCE ERRORS CAUSED BY STANDARD STATISTICAL APPROACHES
TABLE 5 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 6 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 7 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 SERVICES
6.3.1 RISING AI TECHNOLOGY ADOPTION IN VARIOUS END-USE INDUSTRIES TO BOOST MARKET
TABLE 8 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 9 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 10 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
FIGURE 33 MACHINE LEARNING SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022
TABLE 11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 MACHINE LEARNING
FIGURE 34 DEEP LEARNING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 12 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 13 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 14 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 15 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 DEEP LEARNING
7.2.1.1 Growing demand for accelerated genome sequencing analysis workflows and improved function of gene editing tools to propel market
TABLE 16 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 SUPERVISED LEARNING
7.2.2.1 To help create predictive models for population health management
TABLE 19 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 REINFORCEMENT LEARNING
7.2.3.1 Need to reduce costs associated with collecting labeled training data to drive segment
TABLE 22 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.4 UNSUPERVISED LEARNING
7.2.4.1 Ability to perform more complex processing tasks than supervised learning systems to drive market
TABLE 25 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 26 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
TABLE 28 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 29 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 OTHER TECHNOLOGIES
TABLE 31 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
8.1 INTRODUCTION
FIGURE 35 GENOME SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 34 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
8.2 GENOME SEQUENCING
8.2.1 INCREASING ADOPTION OF MACHINE AND DEEP LEARNING IN DIAGNOSTICS AND DRUG DISCOVERY PROCESSES TO ENHANCE MARKET GROWTH
TABLE 35 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 GENE EDITING
8.3.1 TO HELP IMPROVE GENE EDITING FUNCTIONS AND REDUCE TIME AND COSTS
TABLE 38 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 39 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 CLINICAL WORKFLOW
8.4.1 TO HELP INCREASE EFFICIENCY OF CLINICAL WORKFLOWS
TABLE 41 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 42 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE
8.5.1 AI IN GENOMICS TO PREDICT OUTCOMES AND RISKS ASSOCIATED WITH CURING GENETIC DISEASES BASED ON AVAILABLE DATA
TABLE 44 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
9.1 INTRODUCTION
FIGURE 36 DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 47 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 AI IN GENOMICS FOR DIAGNOSTICS TO HELP IDENTIFY CHROMOSOMAL DISORDERS, DYSMORPHIC SYNDROMES, TERATOGENIC DISORDERS, AND SINGLE-GENE DISORDERS
TABLE 48 INDICATIVE LIST OF DEVELOPMENTS FOR DIAGNOSTICS APPLICATION
TABLE 49 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 GROWING APPLICATION OF AI IN GENOMICS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
TABLE 52 INDICATIVE LIST OF DEVELOPMENTS FOR DRUG DELIVERY & DISCOVERY APPLICATION
TABLE 53 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 54 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 PRECISION MEDICINE
9.4.1 FOCUSE ON IDENTIFYING EFFECTIVE MEDICAL TREATMENTS FOR PATIENTS TO DRIVE MARKET
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS FOR PRECISION MEDICINE APPLICATION
TABLE 57 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 58 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 AGRICULTURE & ANIMAL RESEARCH
9.5.1 AI IN GENOMICS TO HELP IMPROVE CROP AND LIVESTOCK PRODUCTIVITY
TABLE 60 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 63 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 64 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
10.1 INTRODUCTION
FIGURE 37 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 66 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 RISING DEMAND FOR SOLUTIONS TO REDUCE TIME AND COSTS OF DRUG DEVELOPMENT
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: INDICATIVE DEVELOPMENTS
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
10.3.1 INCREASED RESEARCH ACTIVITIES TO ENCOURAGE USE OF AI IN GENOMICS IN ACADEMIC AND GOVERNMENT INSTITUTES
TABLE 71 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: INDICATIVE DEVELOPMENTS
TABLE 72 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 73 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10.4 HOSPITALS & HEALTHCARE PROVIDERS
10.4.1 GROWING DEMAND FOR PHARMACOGENOMICS TO PROPEL ACCEPTANCE OF NGS IN HOSPITALS
TABLE 75 HOSPITALS & HEALTHCARE PROVIDERS: INDICATIVE DEVELOPMENTS
TABLE 76 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10.5 OTHER END USERS
TABLE 79 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 80 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
11.1 INTRODUCTION
FIGURE 38 ASIA PACIFIC TO EMERGE AS NEW HOTSPOT DURING FORECAST PERIOD
FIGURE 39 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 82 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT
TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 US
11.2.2.1 Initiatives to accelerate genomic research and growing adoption of AI to bolster market
TABLE 90 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 91 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 92 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 94 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 95 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing research in genomics to drive market
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Adoption of AI in genomics for drug discovery to fuel market
TABLE 109 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 110 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 112 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 113 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 114 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 GERMANY
11.3.3.1 Availability of funding for AI initiatives to boost market
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Increasing government investments in NGS to boost market
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 122 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 123 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 REST OF EUROPE
TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT
TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5 REST OF THE WORLD
11.5.1 REST OF THE WORLD: RECESSION IMPACT
TABLE 139 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 140 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 141 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 143 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY MARKET PLAYERS’ STRATEGIES/RIGHT TO WIN
TABLE 145 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
FIGURE 42 KEY DEVELOPMENTS BY MAJOR MARKET PLAYERS BETWEEN JANUARY 2020 AND MARCH 2023
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS, 2022
FIGURE 43 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS, 2022
12.4 MARKET RANKING ANALYSIS, 2022
FIGURE 44 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SHARE ANALYSIS, 2022
12.5 COMPETITIVE BENCHMARKING
TABLE 146 COMPANY FOOTPRINT ANALYSIS
TABLE 147 PRODUCT FOOTPRINT ANALYSIS (26 COMPANIES)
TABLE 148 FUNCTIONALITY FOOTPRINT ANALYSIS (26 COMPANIES)
TABLE 149 REGIONAL FOOTPRINT ANALYSIS (26 COMPANIES)
12.6 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
12.6.1 STARS
12.6.2 PERVASIVE PLAYERS
12.6.3 EMERGING LEADERS
12.6.4 PARTICIPANTS
FIGURE 45 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
12.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
12.7.1 PROGRESSIVE COMPANIES
12.7.2 DYNAMIC COMPANIES
12.7.3 RESPONSIVE COMPANIES
12.7.4 STARTING BLOCKS
FIGURE 46 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
12.8 COMPETITIVE SCENARIOS AND TRENDS
12.8.1 PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 150 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, 2020–2023
12.8.2 DEALS
TABLE 151 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: DEALS, 2020–2023
12.8.3 OTHER DEVELOPMENTS
TABLE 152 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: OTHER DEVELOPMENTS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 NVIDIA CORPORATION
TABLE 153 NVIDIA CORPORATION: COMPANY OVERVIEW
FIGURE 47 NVIDIA CORPORATION: COMPANY SNAPSHOT
TABLE 154 NVIDIA CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 155 NVIDIA CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 156 NVIDIA CORPORATION: DEALS
13.1.2 MICROSOFT CORPORATION
TABLE 157 MICROSOFT CORPORATION: COMPANY OVERVIEW
FIGURE 48 MICROSOFT CORPORATION: COMPANY SNAPSHOT
TABLE 158 MICROSOFT CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 159 MICROSOFT CORPORATION: DEALS
13.1.3 GOOGLE, INC.
TABLE 160 GOOGLE, INC.: COMPANY OVERVIEW
FIGURE 49 GOOGLE, INC.: COMPANY SNAPSHOT, 2022
TABLE 161 GOOGLE, INC.: PRODUCTS/SERVICES OFFERED
TABLE 162 GOOGLE, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 163 GOOGLE, INC.: DEALS
13.1.4 INTEL CORPORATION
TABLE 164 INTEL CORPORATION: COMPANY OVERVIEW
FIGURE 50 INTEL CORPORATION: COMPANY SNAPSHOT
TABLE 165 INTEL CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 166 INTEL CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 167 INTEL CORPORATION: DEALS
13.1.5 BENEVOLENTAI
TABLE 168 BENEVOLENTAI: COMPANY OVERVIEW
FIGURE 51 BENEVOLENTAI: COMPANY SNAPSHOT
TABLE 169 BENEVOLENTAI: PRODUCTS/SERVICES OFFERED
TABLE 170 BENEVOLENTAI: DEALS
13.1.6 SOPHIA GENETICS
TABLE 171 SOPHIA GENETICS: COMPANY OVERVIEW
FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT
TABLE 172 SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED
TABLE 173 SOPHIA GENOMICS: DEALS
TABLE 174 SOPHIA GENETICS: OTHERS
13.1.7 ILLUMINA, INC.
TABLE 175 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 176 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 177 ILLUMINA, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 178 ILLUMINA, INC.: DEALS
13.1.8 PREDICTIVE ONCOLOGY, INC.
TABLE 179 PREDICTIVE ONCOLOGY, INC.: COMPANY OVERVIEW
FIGURE 54 PREDICTIVE ONCOLOGY, INC.: COMPANY SNAPSHOT
TABLE 180 PREDICTIVE ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED
TABLE 181 PREDICTIVE ONCOLOGY, INC.: DEALS
13.1.9 INVITAE CORPORATION
TABLE 182 INVITAE CORPORATION: COMPANY OVERVIEW
FIGURE 55 INVITAE CORPORATION: COMPANY SNAPSHOT, 2022
TABLE 183 INVITAE CORPORATION: PRODUCTS/SERVICES OFFERED
13.1.10 DEEP GENOMICS, INC.
TABLE 184 DEEP GENOMICS, INC.: COMPANY OVERVIEW
TABLE 185 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 186 DEEP GENOMICS, INC.: DEALS
TABLE 187 DEEP GENOMICS, INC.: OTHERS
13.1.11 FABRIC GENOMICS, INC.
TABLE 188 FABRIC GENOMICS, INC.: COMPANY OVERVIEW
TABLE 189 FABRIC GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 190 FABRIC GENOMICS, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 191 FABRIC GENOMICS, INC.: DEALS
13.1.12 VERGE GENOMICS
TABLE 192 VERGE GENOMICS: COMPANY OVERVIEW
TABLE 193 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED
TABLE 194 VERGE GENOMICS: DEALS
13.1.13 FREENOME HOLDINGS, INC.
TABLE 195 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW
TABLE 196 FREENOME HOLDINGS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 197 FREENOME HOLDINGS, INC.: DEALS
13.1.14 MOLECULARMATCH, INC.
TABLE 198 MOLECULARMATCH, INC.: COMPANY OVERVIEW
TABLE 199 MOLECULARMATCH, INC.: PRODUCTS/SERVICES OFFERED
13.1.15 DANTE LABS
TABLE 200 DANTE LABS: COMPANY OVERVIEW
TABLE 201 DANTE LABS: PRODUCTS/SERVICES OFFERED
TABLE 202 DANTE LABS: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 203 DANTE LABS: DEALS
13.1.16 DATA4CURE
TABLE 204 DATA4CURE: COMPANY OVERVIEW
TABLE 205 DATA4CURE: PRODUCTS/SERVICES OFFERED
13.1.17 PRECISIONLIFE LTD
TABLE 206 PRECISIONLIFE LTD: COMPANY OVERVIEW
TABLE 207 PRECISIONLIFE LTD: PRODUCTS/SERVICES OFFERED
TABLE 208 PRECISIONLIFE LTD: DEALS
13.1.18 GENOOX
TABLE 209 GENOOX: COMPANY OVERVIEW
TABLE 210 GENOOX: PRODUCTS/SERVICES OFFERED
TABLE 211 GENOOX: DEALS
13.1.19 LIFEBIT
TABLE 212 LIFEBIT: COMPANY OVERVIEW
TABLE 213 LIFEBIT: PRODUCTS/SERVICES OFFERED
TABLE 214 LIFEBIT: DEALS
TABLE 215 LIFEBIT: OTHERS
13.2 OTHER EMERGING PLAYERS
13.2.1 FDNA, INC.
13.2.2 DNANEXUS
13.2.3 ENGINE BIOSCIENCES
13.2.4 TEMPUS LABS, INC.
13.2.5 CONGENICA LTD
13.2.6 EMEDGENE, INC.
13.2.7 SERAGON PHARMACEUTICALS, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.5 YEARS CONSIDERED
1.6 CURRENCY CONSIDERED
TABLE 1 CURRENCY CONVERSION RATES
1.7 LIMITATIONS
1.8 STAKEHOLDERS
1.9 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
FIGURE 3 RESEARCH APPROACH
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 KEY METRICS FOR ASSESSING SUPPLY OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
FIGURE 7 REVENUES GENERATED BY COMPANIES FROM SALE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS SOLUTIONS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 9 BOTTOM-UP APPROACH
FIGURE 10 ESTIMATION OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SIZE BASED ON ADOPTION
FIGURE 11 TOP-DOWN APPROACH
TABLE 2 FACTOR ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
FIGURE 13 ASSUMPTIONS FOR RESEARCH STUDY
2.5 IMPACT OF RECESSION
2.6 RISK ASSESSMENT
TABLE 3 LIMITATIONS AND ASSOCIATED RISKS
2.7 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE 14 SOFTWARE SEGMENT TO LEAD ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
FIGURE 15 MACHINE LEARNING CONTINUES TO ACQUIRE LARGEST SIZE OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
FIGURE 16 DEEP LEARNING TO BE FASTEST-GROWING SEGMENT OF ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING
FIGURE 17 GENOME SEQUENCING TO REGISTER HIGHEST CAGR IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
FIGURE 18 DIAGNOSTICS TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SECURE LEADING POSITION IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
FIGURE 20 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
FIGURE 21 INCREASING ADOPTION OF ARTIFICIAL INTELLIGENCE (AI) SOLUTIONS FOR DRUG DISCOVERY & DEVELOPMENT AND PRECISION MEDICINE TO DRIVE MARKET
4.2 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
FIGURE 22 NORTH AMERICA TO DOMINATE ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET DURING FORECAST PERIOD
4.3 NORTH AMERICAN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER AND COUNTRY, 2022
FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US DOMINATED MARKET IN NORTH AMERICA IN 2022
4.4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
FIGURE 24 SOFTWARE SEGMENT TO HOLD MAJORITY MARKET SHARE IN 2028
4.5 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
FIGURE 25 MACHINE LEARNING TO SURPASS OTHER TECHNOLOGIES IN 2028
4.6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028
4.7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
FIGURE 27 GENOME SEQUENCING TO BE FASTEST-GROWING SEGMENT DURING FORECAST PERIOD
4.8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
FIGURE 28 DIAGNOSTICS TO DOMINATE MARKET IN 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Need to accelerate processes and timeline and reduce drug development & discovery costs
5.2.1.2 Increased partnerships and collaborations among players and growing investments in AI in genomics
5.2.1.3 Rising adoption of AI in precision medicine
5.2.1.4 Explosion in bioinformatics data and genomic datasets
FIGURE 29 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023
5.2.1.5 Improving computing power and declining hardware cost
5.2.2 RESTRAINTS
5.2.2.1 Lack of skilled AI workforce and ambiguous regulatory guidelines for medical software
5.2.3 OPPORTUNITIES
5.2.3.1 Focus on developing human-aware AI systems
5.2.4 CHALLENGES
5.2.4.1 Lack of curated genomic data
5.2.4.2 Data privacy concerns
FIGURE 30 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2019–2021
5.3 ECOSYSTEM ANALYSIS
FIGURE 31 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: ECOSYSTEM ANALYSIS
6 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING
6.1 INTRODUCTION
FIGURE 32 SOFTWARE SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022
TABLE 4 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
6.2 SOFTWARE
6.2.1 INTELLIGENT SOFTWARE TO REDUCE ERRORS CAUSED BY STANDARD STATISTICAL APPROACHES
TABLE 5 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 6 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 7 SOFTWARE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 SERVICES
6.3.1 RISING AI TECHNOLOGY ADOPTION IN VARIOUS END-USE INDUSTRIES TO BOOST MARKET
TABLE 8 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 9 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 10 SERVICES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
FIGURE 33 MACHINE LEARNING SEGMENT ACCOUNTED FOR LARGER MARKET SHARE IN 2022
TABLE 11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 MACHINE LEARNING
FIGURE 34 DEEP LEARNING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 12 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 13 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 14 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 15 MACHINE LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 DEEP LEARNING
7.2.1.1 Growing demand for accelerated genome sequencing analysis workflows and improved function of gene editing tools to propel market
TABLE 16 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 DEEP LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 SUPERVISED LEARNING
7.2.2.1 To help create predictive models for population health management
TABLE 19 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 SUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 REINFORCEMENT LEARNING
7.2.3.1 Need to reduce costs associated with collecting labeled training data to drive segment
TABLE 22 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 REINFORCEMENT LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.4 UNSUPERVISED LEARNING
7.2.4.1 Ability to perform more complex processing tasks than supervised learning systems to drive market
TABLE 25 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 26 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 UNSUPERVISED LEARNING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
TABLE 28 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 29 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 OTHER MACHINE LEARNING TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 OTHER TECHNOLOGIES
TABLE 31 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 OTHER TECHNOLOGIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY
8.1 INTRODUCTION
FIGURE 35 GENOME SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 34 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
8.2 GENOME SEQUENCING
8.2.1 INCREASING ADOPTION OF MACHINE AND DEEP LEARNING IN DIAGNOSTICS AND DRUG DISCOVERY PROCESSES TO ENHANCE MARKET GROWTH
TABLE 35 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 GENOME SEQUENCING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 GENE EDITING
8.3.1 TO HELP IMPROVE GENE EDITING FUNCTIONS AND REDUCE TIME AND COSTS
TABLE 38 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 39 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 GENE EDITING: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 CLINICAL WORKFLOW
8.4.1 TO HELP INCREASE EFFICIENCY OF CLINICAL WORKFLOWS
TABLE 41 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 42 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 CLINICAL WORKFLOW: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE
8.5.1 AI IN GENOMICS TO PREDICT OUTCOMES AND RISKS ASSOCIATED WITH CURING GENETIC DISEASES BASED ON AVAILABLE DATA
TABLE 44 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 PREDICTIVE GENETIC TESTING & PREVENTIVE MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION
9.1 INTRODUCTION
FIGURE 36 DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 47 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 AI IN GENOMICS FOR DIAGNOSTICS TO HELP IDENTIFY CHROMOSOMAL DISORDERS, DYSMORPHIC SYNDROMES, TERATOGENIC DISORDERS, AND SINGLE-GENE DISORDERS
TABLE 48 INDICATIVE LIST OF DEVELOPMENTS FOR DIAGNOSTICS APPLICATION
TABLE 49 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 50 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 DIAGNOSTICS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 GROWING APPLICATION OF AI IN GENOMICS IN DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
TABLE 52 INDICATIVE LIST OF DEVELOPMENTS FOR DRUG DELIVERY & DISCOVERY APPLICATION
TABLE 53 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 54 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 DRUG DISCOVERY & DEVELOPMENT: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 PRECISION MEDICINE
9.4.1 FOCUSE ON IDENTIFYING EFFECTIVE MEDICAL TREATMENTS FOR PATIENTS TO DRIVE MARKET
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS FOR PRECISION MEDICINE APPLICATION
TABLE 57 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 58 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 PRECISION MEDICINE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 AGRICULTURE & ANIMAL RESEARCH
9.5.1 AI IN GENOMICS TO HELP IMPROVE CROP AND LIVESTOCK PRODUCTIVITY
TABLE 60 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 AGRICULTURE & ANIMAL RESEARCH: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 63 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 64 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 OTHER APPLICATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER
10.1 INTRODUCTION
FIGURE 37 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 66 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 RISING DEMAND FOR SOLUTIONS TO REDUCE TIME AND COSTS OF DRUG DEVELOPMENT
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: INDICATIVE DEVELOPMENTS
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS
10.3.1 INCREASED RESEARCH ACTIVITIES TO ENCOURAGE USE OF AI IN GENOMICS IN ACADEMIC AND GOVERNMENT INSTITUTES
TABLE 71 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: INDICATIVE DEVELOPMENTS
TABLE 72 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 73 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10.4 HOSPITALS & HEALTHCARE PROVIDERS
10.4.1 GROWING DEMAND FOR PHARMACOGENOMICS TO PROPEL ACCEPTANCE OF NGS IN HOSPITALS
TABLE 75 HOSPITALS & HEALTHCARE PROVIDERS: INDICATIVE DEVELOPMENTS
TABLE 76 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 77 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 HOSPITALS & HEALTHCARE PROVIDERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
10.5 OTHER END USERS
TABLE 79 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 80 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN NORTH AMERICA, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 OTHER END USERS: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
11 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION
11.1 INTRODUCTION
FIGURE 38 ASIA PACIFIC TO EMERGE AS NEW HOTSPOT DURING FORECAST PERIOD
FIGURE 39 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
TABLE 82 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT
TABLE 83 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 85 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 US
11.2.2.1 Initiatives to accelerate genomic research and growing adoption of AI to bolster market
TABLE 90 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 91 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 92 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 93 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 94 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 95 US: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing research in genomics to drive market
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 102 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 UK
11.3.2.1 Adoption of AI in genomics for drug discovery to fuel market
TABLE 109 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 110 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 111 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 112 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 113 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 114 UK: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 GERMANY
11.3.3.1 Availability of funding for AI initiatives to boost market
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Increasing government investments in NGS to boost market
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 122 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 123 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 REST OF EUROPE
TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SNAPSHOT
TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5 REST OF THE WORLD
11.5.1 REST OF THE WORLD: RECESSION IMPACT
TABLE 139 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)
TABLE 140 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 141 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY FUNCTIONALITY, 2021–2028 (USD MILLION)
TABLE 143 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 REST OF THE WORLD: ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY MARKET PLAYERS’ STRATEGIES/RIGHT TO WIN
TABLE 145 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET
FIGURE 42 KEY DEVELOPMENTS BY MAJOR MARKET PLAYERS BETWEEN JANUARY 2020 AND MARCH 2023
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS, 2022
FIGURE 43 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS, 2022
12.4 MARKET RANKING ANALYSIS, 2022
FIGURE 44 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET SHARE ANALYSIS, 2022
12.5 COMPETITIVE BENCHMARKING
TABLE 146 COMPANY FOOTPRINT ANALYSIS
TABLE 147 PRODUCT FOOTPRINT ANALYSIS (26 COMPANIES)
TABLE 148 FUNCTIONALITY FOOTPRINT ANALYSIS (26 COMPANIES)
TABLE 149 REGIONAL FOOTPRINT ANALYSIS (26 COMPANIES)
12.6 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS
12.6.1 STARS
12.6.2 PERVASIVE PLAYERS
12.6.3 EMERGING LEADERS
12.6.4 PARTICIPANTS
FIGURE 45 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
12.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
12.7.1 PROGRESSIVE COMPANIES
12.7.2 DYNAMIC COMPANIES
12.7.3 RESPONSIVE COMPANIES
12.7.4 STARTING BLOCKS
FIGURE 46 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
12.8 COMPETITIVE SCENARIOS AND TRENDS
12.8.1 PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 150 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, 2020–2023
12.8.2 DEALS
TABLE 151 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: DEALS, 2020–2023
12.8.3 OTHER DEVELOPMENTS
TABLE 152 ARTIFICIAL INTELLIGENCE (AI) IN GENOMICS MARKET: OTHER DEVELOPMENTS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 NVIDIA CORPORATION
TABLE 153 NVIDIA CORPORATION: COMPANY OVERVIEW
FIGURE 47 NVIDIA CORPORATION: COMPANY SNAPSHOT
TABLE 154 NVIDIA CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 155 NVIDIA CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 156 NVIDIA CORPORATION: DEALS
13.1.2 MICROSOFT CORPORATION
TABLE 157 MICROSOFT CORPORATION: COMPANY OVERVIEW
FIGURE 48 MICROSOFT CORPORATION: COMPANY SNAPSHOT
TABLE 158 MICROSOFT CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 159 MICROSOFT CORPORATION: DEALS
13.1.3 GOOGLE, INC.
TABLE 160 GOOGLE, INC.: COMPANY OVERVIEW
FIGURE 49 GOOGLE, INC.: COMPANY SNAPSHOT, 2022
TABLE 161 GOOGLE, INC.: PRODUCTS/SERVICES OFFERED
TABLE 162 GOOGLE, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 163 GOOGLE, INC.: DEALS
13.1.4 INTEL CORPORATION
TABLE 164 INTEL CORPORATION: COMPANY OVERVIEW
FIGURE 50 INTEL CORPORATION: COMPANY SNAPSHOT
TABLE 165 INTEL CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 166 INTEL CORPORATION: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 167 INTEL CORPORATION: DEALS
13.1.5 BENEVOLENTAI
TABLE 168 BENEVOLENTAI: COMPANY OVERVIEW
FIGURE 51 BENEVOLENTAI: COMPANY SNAPSHOT
TABLE 169 BENEVOLENTAI: PRODUCTS/SERVICES OFFERED
TABLE 170 BENEVOLENTAI: DEALS
13.1.6 SOPHIA GENETICS
TABLE 171 SOPHIA GENETICS: COMPANY OVERVIEW
FIGURE 52 SOPHIA GENETICS: COMPANY SNAPSHOT
TABLE 172 SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED
TABLE 173 SOPHIA GENOMICS: DEALS
TABLE 174 SOPHIA GENETICS: OTHERS
13.1.7 ILLUMINA, INC.
TABLE 175 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 53 ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 176 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED
TABLE 177 ILLUMINA, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 178 ILLUMINA, INC.: DEALS
13.1.8 PREDICTIVE ONCOLOGY, INC.
TABLE 179 PREDICTIVE ONCOLOGY, INC.: COMPANY OVERVIEW
FIGURE 54 PREDICTIVE ONCOLOGY, INC.: COMPANY SNAPSHOT
TABLE 180 PREDICTIVE ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED
TABLE 181 PREDICTIVE ONCOLOGY, INC.: DEALS
13.1.9 INVITAE CORPORATION
TABLE 182 INVITAE CORPORATION: COMPANY OVERVIEW
FIGURE 55 INVITAE CORPORATION: COMPANY SNAPSHOT, 2022
TABLE 183 INVITAE CORPORATION: PRODUCTS/SERVICES OFFERED
13.1.10 DEEP GENOMICS, INC.
TABLE 184 DEEP GENOMICS, INC.: COMPANY OVERVIEW
TABLE 185 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 186 DEEP GENOMICS, INC.: DEALS
TABLE 187 DEEP GENOMICS, INC.: OTHERS
13.1.11 FABRIC GENOMICS, INC.
TABLE 188 FABRIC GENOMICS, INC.: COMPANY OVERVIEW
TABLE 189 FABRIC GENOMICS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 190 FABRIC GENOMICS, INC.: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 191 FABRIC GENOMICS, INC.: DEALS
13.1.12 VERGE GENOMICS
TABLE 192 VERGE GENOMICS: COMPANY OVERVIEW
TABLE 193 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED
TABLE 194 VERGE GENOMICS: DEALS
13.1.13 FREENOME HOLDINGS, INC.
TABLE 195 FREENOME HOLDINGS, INC.: COMPANY OVERVIEW
TABLE 196 FREENOME HOLDINGS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 197 FREENOME HOLDINGS, INC.: DEALS
13.1.14 MOLECULARMATCH, INC.
TABLE 198 MOLECULARMATCH, INC.: COMPANY OVERVIEW
TABLE 199 MOLECULARMATCH, INC.: PRODUCTS/SERVICES OFFERED
13.1.15 DANTE LABS
TABLE 200 DANTE LABS: COMPANY OVERVIEW
TABLE 201 DANTE LABS: PRODUCTS/SERVICES OFFERED
TABLE 202 DANTE LABS: PRODUCT LAUNCHES/ENHANCEMENTS
TABLE 203 DANTE LABS: DEALS
13.1.16 DATA4CURE
TABLE 204 DATA4CURE: COMPANY OVERVIEW
TABLE 205 DATA4CURE: PRODUCTS/SERVICES OFFERED
13.1.17 PRECISIONLIFE LTD
TABLE 206 PRECISIONLIFE LTD: COMPANY OVERVIEW
TABLE 207 PRECISIONLIFE LTD: PRODUCTS/SERVICES OFFERED
TABLE 208 PRECISIONLIFE LTD: DEALS
13.1.18 GENOOX
TABLE 209 GENOOX: COMPANY OVERVIEW
TABLE 210 GENOOX: PRODUCTS/SERVICES OFFERED
TABLE 211 GENOOX: DEALS
13.1.19 LIFEBIT
TABLE 212 LIFEBIT: COMPANY OVERVIEW
TABLE 213 LIFEBIT: PRODUCTS/SERVICES OFFERED
TABLE 214 LIFEBIT: DEALS
TABLE 215 LIFEBIT: OTHERS
13.2 OTHER EMERGING PLAYERS
13.2.1 FDNA, INC.
13.2.2 DNANEXUS
13.2.3 ENGINE BIOSCIENCES
13.2.4 TEMPUS LABS, INC.
13.2.5 CONGENICA LTD
13.2.6 EMEDGENE, INC.
13.2.7 SERAGON PHARMACEUTICALS, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
